RECRUITINGPhase 2INTERVENTIONAL
IVIM & OLINK in Sarcoma
Prospective Study of Image and Blood-derived Biomarkers to Predict Metastasis in Soft-tissue Sarcomas
About This Trial
The hypoxia \> metastasis axis suggests that a DWI-based biomarker of hypoxia incorporating IVIM may be able to predict metastasis in STS patients, ultimately enabling stratification for personalized treatments at the time of diagnostic (MR) imaging, without adding an excessive burden to the patient or clinical workflow (typical DWI/IVIM sequences can be acquired acquired in approximately 5 minutes).
Who May Be Eligible (Plain English)
Who May Qualify:
- Age ≥ 18 years
- Ability to understand and the willingness to sign a written willing to sign a consent form document
- Grade 2 or 3 soft tissue sarcoma greater than 5 cm in largest dimension
Who Should NOT Join This Trial:
- Contraindication to MRI scan as per current institutional guidelines (for patients requiring MRI)
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
* Age ≥ 18 years
* Ability to understand and the willingness to sign a written informed consent document
* Grade 2 or 3 soft tissue sarcoma greater than 5 cm in largest dimension
Exclusion Criteria:
* Contraindication to MRI scan as per current institutional guidelines (for patients requiring MRI)
Treatments Being Tested
RADIATION
Radiotherapy
Standard of care pre-operative radiotherapy
OTHER
Surgery
Standard of care definitive surgery
Locations (1)
University Health Network
Toronto, Ontario, Canada